Macrogenics Inc
A biotech company that engineers antibody-based therapies to fight cancer. Its drug MARGENZA was approved in 2020 for HER2-positive breast cancer, and its DART platform builds proteins that bind two targets at once, steering immune cells toward tumors. Founded in 2000 in Rockville, Maryland, by a team of scientists, its name combines "macro," for the large protein molecules it builds, with "genics," echoing genetic engineering.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 13G/APassive | 7.88% | 5.01M | Aug 14, 2026 |
| Steven Boyd | 13G/APassive | 7.88% | 5.01M | Aug 14, 2026 |
| BANK OF AMERICA CORP /DE/ | 13G/APassive | 4% | 2.56M | Aug 3, 2026 |
| BlackRock, Inc. | 13GPassive | 7.1% | 4.50M | Jul 29, 2026 |
| Millennium Management LLC | 13G/APassive | 3.7% | 2.37M | Jul 20, 2026 |
| Millennium Group Management LLC | 13G/APassive | 3.7% | 2.37M | Jul 20, 2026 |
| Israel A. Englander | 13G/APassive | 3.7% | 2.37M | Jul 20, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |
| Frazier Life Sciences Public Fund, L.P. | 13G/APassive | 0% | 0 | Feb 13, 2026 |
| FHMLSP, L.P. | 13G/APassive | 0% | 0 | Feb 13, 2026 |